source
- Moderna’s melanoma vaccine trial success sparks $45 billion market value surgeModerna’s shares jumped more than 170% after the company announced that its experimental melanoma vaccine, intismeran, met its primary goals in a Phase 3 trial. The surge added roughly $45 billion…
- Moderna and Merck cancer vaccine returns ‘landmark’ result in melanomaAt an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.BioPharma Dive · 1d ago↗ source